Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients

Gundeep S. Dhillon, Vincent G. Valentine, Joseph Levitt, Premal Patel, Meera R. Gupta, Steven R. Duncan, Leonardo Seoane, David Weill

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Bronchiolitis obliterans syndrome (BOS) is the major limitation to long-term survival following lung transplantation and strategies to reduce its incidence have remained elusive. Macrolides may stabilize lung function in patients with established BOS. Their role, however, in prevention of BOS remains unexamined. Methods: Survival and BOS-free survival of 102 lung allograft recipients (LARs), transplanted at a single center between July 1995 and December 2001 who routinely received clarithromycin, were compared with two different control groups. The first control group consisted of 44 LARs from the same center who were transplanted from January 2002 onwards and did not receive clarithromycin. The second control group consisted of a contemporaneous cohort of 5089 recipients, transplanted between 1995 and 2001, reported to the United Network for Organ Sharing database. Results: When compared with the first control group, BOS-free survival was reduced in LARs receiving clarithromycin. Univariate (hazard ratio [HR] 3.13, p-value=0.004) and multivariate (HR 3.49, p-value=0.04) analyses showed that routine use of clarithromycin was associated with an increased risk of developing BOS. When compared with the second control group, the five-yr survival of clarithromycin group was similar (p-value=0.24). Conclusions: Routine use of clarithromycin does not delay development of BOS or improve survival.

Original languageEnglish (US)
Pages (from-to)105-110
Number of pages6
JournalClinical Transplantation
Volume26
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Bronchiolitis Obliterans
Clarithromycin
Allografts
Lung
Control Groups
Survival
Lung Transplantation
Macrolides
Databases
Incidence

Keywords

  • Bronchiolitis obliterans syndrome
  • Clarithromycin
  • Lung transplantation
  • Macrolides
  • Prevention

ASJC Scopus subject areas

  • Transplantation

Cite this

Dhillon, G. S., Valentine, V. G., Levitt, J., Patel, P., Gupta, M. R., Duncan, S. R., ... Weill, D. (2012). Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients. Clinical Transplantation, 26(1), 105-110. https://doi.org/10.1111/j.1399-0012.2011.01420.x

Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients. / Dhillon, Gundeep S.; Valentine, Vincent G.; Levitt, Joseph; Patel, Premal; Gupta, Meera R.; Duncan, Steven R.; Seoane, Leonardo; Weill, David.

In: Clinical Transplantation, Vol. 26, No. 1, 01.2012, p. 105-110.

Research output: Contribution to journalArticle

Dhillon, GS, Valentine, VG, Levitt, J, Patel, P, Gupta, MR, Duncan, SR, Seoane, L & Weill, D 2012, 'Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients', Clinical Transplantation, vol. 26, no. 1, pp. 105-110. https://doi.org/10.1111/j.1399-0012.2011.01420.x
Dhillon, Gundeep S. ; Valentine, Vincent G. ; Levitt, Joseph ; Patel, Premal ; Gupta, Meera R. ; Duncan, Steven R. ; Seoane, Leonardo ; Weill, David. / Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients. In: Clinical Transplantation. 2012 ; Vol. 26, No. 1. pp. 105-110.
@article{5b816081ba6e44609ab73fbff9279999,
title = "Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients",
abstract = "Background: Bronchiolitis obliterans syndrome (BOS) is the major limitation to long-term survival following lung transplantation and strategies to reduce its incidence have remained elusive. Macrolides may stabilize lung function in patients with established BOS. Their role, however, in prevention of BOS remains unexamined. Methods: Survival and BOS-free survival of 102 lung allograft recipients (LARs), transplanted at a single center between July 1995 and December 2001 who routinely received clarithromycin, were compared with two different control groups. The first control group consisted of 44 LARs from the same center who were transplanted from January 2002 onwards and did not receive clarithromycin. The second control group consisted of a contemporaneous cohort of 5089 recipients, transplanted between 1995 and 2001, reported to the United Network for Organ Sharing database. Results: When compared with the first control group, BOS-free survival was reduced in LARs receiving clarithromycin. Univariate (hazard ratio [HR] 3.13, p-value=0.004) and multivariate (HR 3.49, p-value=0.04) analyses showed that routine use of clarithromycin was associated with an increased risk of developing BOS. When compared with the second control group, the five-yr survival of clarithromycin group was similar (p-value=0.24). Conclusions: Routine use of clarithromycin does not delay development of BOS or improve survival.",
keywords = "Bronchiolitis obliterans syndrome, Clarithromycin, Lung transplantation, Macrolides, Prevention",
author = "Dhillon, {Gundeep S.} and Valentine, {Vincent G.} and Joseph Levitt and Premal Patel and Gupta, {Meera R.} and Duncan, {Steven R.} and Leonardo Seoane and David Weill",
year = "2012",
month = "1",
doi = "10.1111/j.1399-0012.2011.01420.x",
language = "English (US)",
volume = "26",
pages = "105--110",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients

AU - Dhillon, Gundeep S.

AU - Valentine, Vincent G.

AU - Levitt, Joseph

AU - Patel, Premal

AU - Gupta, Meera R.

AU - Duncan, Steven R.

AU - Seoane, Leonardo

AU - Weill, David

PY - 2012/1

Y1 - 2012/1

N2 - Background: Bronchiolitis obliterans syndrome (BOS) is the major limitation to long-term survival following lung transplantation and strategies to reduce its incidence have remained elusive. Macrolides may stabilize lung function in patients with established BOS. Their role, however, in prevention of BOS remains unexamined. Methods: Survival and BOS-free survival of 102 lung allograft recipients (LARs), transplanted at a single center between July 1995 and December 2001 who routinely received clarithromycin, were compared with two different control groups. The first control group consisted of 44 LARs from the same center who were transplanted from January 2002 onwards and did not receive clarithromycin. The second control group consisted of a contemporaneous cohort of 5089 recipients, transplanted between 1995 and 2001, reported to the United Network for Organ Sharing database. Results: When compared with the first control group, BOS-free survival was reduced in LARs receiving clarithromycin. Univariate (hazard ratio [HR] 3.13, p-value=0.004) and multivariate (HR 3.49, p-value=0.04) analyses showed that routine use of clarithromycin was associated with an increased risk of developing BOS. When compared with the second control group, the five-yr survival of clarithromycin group was similar (p-value=0.24). Conclusions: Routine use of clarithromycin does not delay development of BOS or improve survival.

AB - Background: Bronchiolitis obliterans syndrome (BOS) is the major limitation to long-term survival following lung transplantation and strategies to reduce its incidence have remained elusive. Macrolides may stabilize lung function in patients with established BOS. Their role, however, in prevention of BOS remains unexamined. Methods: Survival and BOS-free survival of 102 lung allograft recipients (LARs), transplanted at a single center between July 1995 and December 2001 who routinely received clarithromycin, were compared with two different control groups. The first control group consisted of 44 LARs from the same center who were transplanted from January 2002 onwards and did not receive clarithromycin. The second control group consisted of a contemporaneous cohort of 5089 recipients, transplanted between 1995 and 2001, reported to the United Network for Organ Sharing database. Results: When compared with the first control group, BOS-free survival was reduced in LARs receiving clarithromycin. Univariate (hazard ratio [HR] 3.13, p-value=0.004) and multivariate (HR 3.49, p-value=0.04) analyses showed that routine use of clarithromycin was associated with an increased risk of developing BOS. When compared with the second control group, the five-yr survival of clarithromycin group was similar (p-value=0.24). Conclusions: Routine use of clarithromycin does not delay development of BOS or improve survival.

KW - Bronchiolitis obliterans syndrome

KW - Clarithromycin

KW - Lung transplantation

KW - Macrolides

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=84856675014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856675014&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2011.01420.x

DO - 10.1111/j.1399-0012.2011.01420.x

M3 - Article

C2 - 21352378

AN - SCOPUS:84856675014

VL - 26

SP - 105

EP - 110

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 1

ER -